Evidence map›Paper›PMID 40924149›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

[

Louis Versweyveld, Aline Delva, Marie Cohilis, Christophe M Deroose, Donatienne Van Weehaeghe, Michel Koole, Wim Vandenberghe, Koen Van Laere

Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06120049 (Prospective Head-to-head Comparison of Cardiac [18F]-MFBG PET Versus [123I]-MIBG SPECT in the Differentiation Between Parkinson's Disease and Multiple System Atrophy and Between Dementia With Lewy Bodies and Alzheimer's Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06120049 phase2 / phase3recruitingnot on this map

Prospective Head-to-head Comparison of Cardiac [18F]-MFBG PET Versus [123I]-MIBG SPECT in the Differentiation Between Parkinson's Disease and Multiple System Atrophy and Between Dementia With Lewy Bodies and Alzheimer's Disease

TypeinterventionalSponsorprof. dr. Koen Van LaereRan2024 to 2026Enrolled113ConditionsParkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer DiseaseArms[18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT, [18F]-MFBG PET dosimetry scans
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. PET imaging of cardiac sympathetic nervous system dysfunction using meta-[European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Louis VersweyveldNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. Louis.versweyveld@gmail.com.ORCID 0009-0008-3475-1079
Aline DelvaDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Marie CohilisNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Christophe M DerooseNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Donatienne Van WeehaegheDepartment of Radiology and Nuclear Medicine, Ghent University hospital, Ghent, Belgium.
Michel KooleNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Wim VandenbergheDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Koen Van LaereNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

Funding

Fonds Wetenschappelijk Onderzoek T001223N
6 · The paper itself

Abstract

purposeCardiac noradrenergic denervation visualized by meta-[

methodsFor dosimetry, three controls underwent sequential whole-body [

resultsMean effective dose was 23.1±2.6 μSv/MBq. [

conclusion[ CLINICAL

trial registrationClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049.

Indexed as

HeartParkinson DiseasePositron Emission Tomography Computed TomographySympathetic Nervous System3-IodobenzylguanidineAgedCase-Control StudiesFemaleHumansMaleMiddle AgedRadiometryRadiopharmaceuticals3-IodobenzylguanidineRadiopharmaceuticals[18F]MFBGDosimetryParkinson’s diseasePETPharmacokinetics

Identifiers

PMID40924149

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.